TELA
TELA Bio Inc

310
Mkt Cap
$45.16M
Volume
189,844.00
52W High
$3.20
52W Low
$0.8645
PE Ratio
-1.02
TELA Fundamentals
Price
$1.11
Prev Close
$1.14
Open
$1.15
50D MA
$1.46
Beta
0.76
Avg. Volume
100,535.00
EPS (Annual)
-$1.33
P/B
4.91
Rev/Employee
$331,578.95
Loading...
Loading...
News
all
press releases
TELA Bio, Inc. (TELA) Reports Q3 Loss, Misses Revenue Estimates
TELA Bio (TELA) delivered earnings and revenue surprises of -11.76% and -5.53%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2h ago
News Placeholder
More News
News Placeholder
Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of +17.65% and -17.71%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1d ago
News Placeholder
Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -200.00% and +1.70%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·8d ago
News Placeholder
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
TELA Bio (TELA) delivered earnings and revenue surprises of -22.22% and -1.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates
Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of -13.89% and -59.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates
Geron (GERN) delivered earnings and revenue surprises of +33.33% and +2.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
NeoGenomics (NEO) Meets Q2 Earnings Estimates
NeoGenomics (NEO) delivered earnings and revenue surprises of 0.00% and -0.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Deutsche Bank initiates coverage on Telekom Austria with “hold” rating
investing.com·5mo ago
News Placeholder
Demystifying TELA Bio: Insights From 6 Analyst Reviews
Latest Ratings for TELA DateFirmActionFromTo Aug 2020Piper SandlerMaintainsOverweight Jul 2020JefferiesMaintainsBuy Jun 2020JMP SecuritiesMaintainsMarket Outperform View More Analyst Ratings...
Benzinga·1y ago

Latest TELA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.